Literature DB >> 28224376

A case of atypical hemolytic uremic syndrome in a second renal transplant.

Nicholas A Zwang1,2,3, Bing Ho4, Yashpal S Kanwar5, Brad Lewis6, Matthew Cusick4, John J Friedewald4,7,5,6,8, Lorenzo Gallon4.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; Complement biology.; Graft failure; Histocompatibility; Kidney transplantation

Mesh:

Substances:

Year:  2017        PMID: 28224376     DOI: 10.1007/s40620-016-0373-7

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  38 in total

1.  Targeting complement C5 in atypical hemolytic uremic syndrome.

Authors:  David J Salant
Journal:  J Am Soc Nephrol       Date:  2010-12-02       Impact factor: 10.121

2.  Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

Authors:  V Chatelet; V Frémeaux-Bacchi; T Lobbedez; M Ficheux; B Hurault de Ligny
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

Review 3.  Complement factor H related proteins (CFHRs).

Authors:  Christine Skerka; Qian Chen; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Mol Immunol       Date:  2013-07-03       Impact factor: 4.407

4.  Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.

Authors:  Hervé Sartelet; Olivier Toupance; Marianne Lorenzato; Fouad Fadel; Laure Hélène Noel; Eymeric Lagonotte; Philippe Birembaut; Jacques Chanard; Philippe Rieu
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

5.  Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?

Authors:  Michael Robson; Isabelle Côte; Ian Abbs; Geoffrey Koffman; David Goldsmith
Journal:  Am J Transplant       Date:  2003-03       Impact factor: 8.086

6.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

7.  Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

Authors:  Jean-Claude Davin; Valentina Gracchi; Antonia Bouts; Jaap Groothoff; Lisa Strain; Tim Goodship
Journal:  Am J Kidney Dis       Date:  2009-10-25       Impact factor: 8.860

8.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

9.  Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.

Authors:  R N Smith; T Kawai; S Boskovic; O Nadazdin; D H Sachs; A B Cosimi; R B Colvin
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

10.  Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.

Authors:  Peter F Zipfel; Matthew Edey; Stefan Heinen; Mihály Józsi; Heiko Richter; Joachim Misselwitz; Bernd Hoppe; Danny Routledge; Lisa Strain; Anne E Hughes; Judith A Goodship; Christoph Licht; Timothy H J Goodship; Christine Skerka
Journal:  PLoS Genet       Date:  2007-02-01       Impact factor: 5.917

View more
  1 in total

Review 1.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Authors:  Kioa L Wijnsma; Caroline Duineveld; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2018-11-06       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.